← Back
Data updated: Mar 10, 2026
AMPHASTAR PHARM
OncologyInfectious DiseaseRespiratory
AMPHASTAR PHARM is a pharmaceutical company focused on Oncology, Infectious Disease, Respiratory.
2004
Since
3
Drugs
-
Trials
58
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
KETOROLAC TROMETHAMINE 2026-01-22
Labeling
ENOXAPARIN SODIUM (PRESERVATIVE FREE) 2026-01-07
ENOXAPARIN SODIUM (PRESERVATIVE FREE) 2025-11-25
Labeling
KETOROLAC TROMETHAMINE 2024-11-21
Labeling
KETOROLAC TROMETHAMINE 2024-11-21
Labeling
KETOROLAC TROMETHAMINE 2024-11-21
Labeling
KETOROLAC TROMETHAMINE 2024-11-21
Labeling
KETOROLAC TROMETHAMINE 2024-11-21
Labeling
KETOROLAC TROMETHAMINE 2024-11-21
Labeling
KETOROLAC TROMETHAMINE 2024-11-21
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 35%
0 drugs Phase 3: 3 Phase 1: 2
Infectious Disease 20%
0 drugs Phase 3: 1 Phase 2: 2
Respiratory 18%
1 drugs Phase 1: 1
Cardiovascular 15%
1 drugs
Dermatology 13%
0 drugs Phase 3: 1 Phase 1: 1
Pipeline Strength Pro
Loading...
Competitors Pro
Baxter specialty
Infectious Disease, Cardiovascular, Oncology, Dermatology
Pfizer big-pharma
Oncology, Infectious Disease, Dermatology
COSETTE other
Cardiovascular, Dermatology, Infectious Disease, Oncology
Novartis big-pharma
Oncology, Cardiovascular, Respiratory
GE HEALTHCARE specialty
Infectious Disease, Cardiovascular, Oncology, Respiratory
Discontinued (0)
Company Info
- First Approval
- 2004-07-21
- Latest
- 2024-11-21
- Applications
- 3